Synthetic lethality on drug discovery: an update on cancer therapy.
Mohammad Shahar YarKashif HaiderVivek GohelNasir Ali SiddiquiAhmed KamalPublished in: Expert opinion on drug discovery (2020)
SL conceptualizes a resolution against treatment resistance to anticancer regimen by recognition of therapeutic vulnerabilities in particular cancer cells. A multitude of clinical trials associated with SL and DNA repair are being conducted that will be useful in obtaining a clearer picture pertaining to the use of cancer biomarkers and effectiveness of drugs acting via target-based molecular changes. Furthermore, new anticancer regimen focused on personalized medicines will emerge basing their development upon SL.